ClariCore System Used in Transperineal Prostate Biopsy

Prostate Cancer Clinical Trial

Official title:

Prospective, Multi-Center Study of the ClariCore Optical Biopsy System in Patients Undergoing Transperineal Prostate Biopsy for Prostate Tissue Classification Algorithm Development

Clinical Trial Details — Status: Suspended

Administrative data

• NCT number: NCT03734575
• Other study ID #: CIP-1012
• Status: Suspended
• Phase: N/A
• Start date: October 10, 2018
• Est. completion date: July 9, 2019

Study information

• Verified date: July 2019
• Source: Precision Biopsy, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The overall objective of this study is to acquire ultrasound images, spectral data and prostate tissue biopsy cores using the ClariCore System via a transperineal approach.

Description:

The overall objective of this study is to acquire ultrasound images, spectral data and prostate tissue biopsy cores using the ClariCore System via a transperineal approach. Ultrasound images corresponding to each needle insertion and T2-weighted MR scans will be saved for the purpose of further algorithm development that will provide physicians with real time tissue classification in conjunction with location information from the ultrasound imaging.

Recruitment information / eligibility

• Status: Suspended
• Enrollment: 60
• Est. completion date: July 9, 2019
• Est. primary completion date: July 9, 2019
• Accepts healthy volunteers: No
• Gender: Male
• Age group: N/A and older

Eligibility

Inclusion Criteria:

1. Males per Investigator assessment appropriate for transperineal prostate biopsy

2. Patient scheduled for transperineal prostate biopsy based on standard of care urologic requirements to assess for tissue malignancy

3. Prostate volume > 20cc and length at least 22mm as verified by ultrasound or prostate MRI prior to the procedure

4. Patient must be able to provide legal consent and signs an IRB (Institutional Review Board)/EC (Ethics Committee) approved Informed Consent form to participate in the study prior to any study mandated determinations or procedure

Exclusion Criteria:

1. Any anatomical or co-morbidity contraindications to transperineal prostate biopsy or transperineal prostate mapping biopsy

2. Acute painful perianal disorder (i.e. rectal abscess)

3. Symptomatic, acute prostatitis

4. Surgical absence of a rectum or the presence of a rectal fistula

5. Patient has systemic infection or evidence of any surgical site infection (superficial or organ space), including active urinary tract infection

6. Previous prostate intervention [TURP (bipolar, monopolar, laser)] TUMT, HIFU, Cryo, Rezum, Urolift], not including previous prostate biopsy

7. Current required use of blood thinning agents for medical comorbidity which prohibits the cessation of use as typically required per standard of care (SOC) prior to a medical procedure; or history of a bleeding disorder (e.g. coagulopathy)

8. Prior pelvic irradiation

9. Actively receiving therapy for the treatment of cancer (except for patients on 5-alpha reductase inhibitors, or non-melanoma skin cancers that are managed nonsystemically)

10. Actively receiving intravesical therapy or within 6 months of treatment for bladder cancer

11. Patient has compromised immune system, in the opinion of the Investigator

12. Active inflammatory bowel disease within the last 6 months

13. Any condition, or history of illness or surgery that, in the opinion of the Investigator, might confound the results of the study or pose additional risks to the patient (e.g.

significant cardiovascular conditions or allergies)

14. Patient is not likely to comply with the protocol or follow up evaluation

15. Patient is participating in a clinical trial of another investigational drug or device that may impact participation in this clinical study

Related Conditions & MeSH terms

• Prostate Cancer

Intervention

Device:
• ClariCore System
The user will perform a standard trans-perineal biopsy and collect a number of biopsy cores as per standard practice.

Locations

Country	Name	City	State
United States	The James Buchanan Brady Urological Institute and Department of Urology	Baltimore	Maryland
United States	NYU Langone Urology Associates	New York	New York

Sponsors (1)

Lead Sponsor	Collaborator
Precision Biopsy, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Correlation of histopathology of tissue with ultrasound images and spectral data	The correlation of histopathology of tissue biopsy core samples with the corresponding spectral data and ultrasound images obtained in vivo for the purpose of tissue classification algorithm development using a transperineal approach.	At time of procedure
Secondary	Incidence of Adverse Events (Safety)	The cumulative incidence of adverse events related to the device or the procedure. The cumulative incidence of serious adverse events (SAEs) related to the device or the procedure.	At time of procedure